Authors

Latest:

CLL in the Era of Targeted Therapies

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Kanwal Raghav, MBBS, MD

Latest:

Dr Raghav on ABBV-400 Plus 5-FU, Folinic Acid, and Bevacizumab in Previously Treated mCRC

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Kanwal Raghav, MD

Latest:

Metastatic Colorectal Cancer: Future Directions in Care

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Kapil N. Bhalla, MD

Latest:

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Kapodistrian University of Athens School of Medicine

Kara D. Forinash, MS, PA-C, Shari Pilon-Thomas, PhD

Latest:

Immunotherapy Combined With Chemotherapy for Pancreatic Cancer: A Game Changer?

This article reviews up-to-date clinical studies combining chemotherapy with immunotherapy; it also explains the rationale for this combination in treatment of pancreatic cancer.

Kareem Abdul-Jabbar

Latest:

Kareem Abdul-Jabbar Discusses Living With CML

Kareem Abdul-Jabbar, retired NBA player for the Milwaukee Bucks and the Los Angeles Lakers, discusses his experience with chronic myeloid leukemiaâ€Ž (CML) at the 20th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma, held March 18.

Karen E. Hoffman, MD

Latest:

Dr. Hoffman on the Urologist's Influence on Treatment Choice

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.

Karen E. Knudsen, PhD

Latest:

The Rationale for Investigating DNA-PK as a Target in Prostate Cancer

Karen E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.

Karen H. Lu, MD

Latest:

Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer

Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.

Karen H. Ventii, PhD

Latest:

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

Karen Hagemaster, RN, BSN

Latest:

Karen Hagemaster on Chemo Documentation Study

Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study

Karen Hande, DNP, ANP-BC, CNE

Latest:

Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer Care

Opioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.

Karen J. Ayers, ACNP

Latest:

Innovative Use of Technology for Palliative Care

Innovative models for palliative care delivery and primary palliative care training are springing up to address the demandâ€“capacity mismatch.

Karen K. Ballen, MD

Latest:

Most Patients in Need of HCT Can Now Get Transplants

Due to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.

Karen Kellogg, PharmD

Latest:

The Importance of the Oncologist in Physician Dispensing

Karen Kellogg, PharmD, Cardinal Health, discusses the important role that the oncologist plays in dispensing.

Karen Kelly, MD

Latest:

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Karen Kelly, MD, UC Davis Comprehensive Cancer Center

Karen Knudsen, PhD

Latest:

Lynchpin Molecule for Cancer Metastasis Found

A single molecule called DNA-PKcs may drive metastatic processes that turn cancer from a slowly growing, relatively benign disease to a killer.

Karen L. Reckamp, MD, MS

Latest:

Dr Reckamp on Emerging EGFR TKIs in EGFR Exon 20 Insertion+ NSCLC

Karen L. Reckamp, MD, MS, discusses emerging EGFR TKIs in EGFR Exon 20–Mutated NSCLC.